Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a first of its kind study into the population and spread of tuberculosis-causing (TB) bacteria in Ho Chi Minh City, Thuong Thuong Nguyn and collegues at OUCRU Vietnam, Australia, UK and Singapore have found that more than half of cases can be attributed to one particular strain of the bacteria.

TB  MDR-TB  TB/HIV

Using state-of-the-art genomics technology, a Melbourne-led international collaboration, including researchers from OUCRU in Vietnam and Singapore, sequenced the DNA from bacteria isolated from the lungs of 1635 TB patients located in outpatient clinics in eight districts of Ho Chi Minh City. The findings, published in Nature Genetics this week, concluded that the strain of TB-causing bacteria known as the Beijing lineage, was responsible for 59 per cent of infections, and even more (75%) of those diagnosed in younger people.

TB is the leading cause of death globally from a single infectious agent – Mycobacterium tuberculosis – that typically affects the lungs, but can also infect other sites of the body. Multiple antibiotics are used to treat TB, however treatment is long (six months), and the emergence of drug-resistant bacteria is a considerable threat to global health.

Vietnam is one of the WHO High Burden Countries for TB and multi drug-resistant TB, and in 2016 there were an estimated 126,000 cases and 13,850 deaths in the South East Asian country. Co-lead Investigator of the study and a Senior Research Fellow, Dr Sarah Dunstan from the Peter Doherty Institute for Infection and Immunity (a joint venture of The University of Melbourne and The Royal Melbourne Hospital), said within the Beijing lineage they found a mutation, which likely bolsters the bacteria’s ability to spread. “Combating and managing TB spread requires new strategies to diagnose, treat and protect against emerging and evolving strains of the bacteria,” said Dr Dunstan. “Armed with an understanding of how the disease is spread in Ho Chi Minh City could allow more targeted local TB control, and this knowledge could potentially be applied to other settings given the Beijing lineage is found worldwide, predominantly in Asia.”

First author on the paper describing the study, Associate Professor Kathryn Holt from the University of Melbourne’s Bio21 Molecular Science and Biotechnology Institute, said the study shows the Beijing lineage of TB bacteria spreads more easily from person-to-person than other strains of the bacteria. “Contact tracing – looking for early signs of TB infection in people who have been in close contact with TB patients, and treating them before they can spread the disease further – is an important part of TB control, but it takes a lot of resources,” said Associate Professor Holt. “All TB patients have the potential to transmit the TB bacteria to others when they cough, but our data indicates this is more likely to result in new disease cases if the infection is caused by the Beijing lineage. So if resources are limited, it would make sense to prioritise contact tracing for Beijing lineage TB cases.”

Co-author Dr Nguyen T. T. Thuong, head of OUCRU’s TB group in Ho Chi Minh City, comments: “TB treatment fails in many patients infected with multidrug resistant strains, which are then passed on, increasing the number of resistant cases in the community. My team in Vietnam now is running a pilot study in early diagnosis of drug resistant TB cases using whole genome sequencing. The findings from this publication can be applied concurrently to identify those carrying the easily-spread-mutation. If this test becomes a bedside diagnostic tool, it will allow not only early diagnosis of drug resistance and more precise treatment but also better management against disease transmission.”

The study was funded by the National Health and Medical Research Council in Australia, Wellcome Trust UK and A*STAR Biomedical Research Council Singapore.

Similar stories

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

What does the Oxford Malaria vaccine mean for Asia?

A trial in infants and toddlers in Burkina Faso showed that experimental malaria vaccine R21/MM confers 77% protection, an unprecedented level and the first malaria vaccine to exceed WHO’s goal of 75% efficacy. While a larger trial is needed to assess its safety and efficacy, R21/MM may substantially reduce child mortality in Sub-Saharan Africa. But this vaccine may be less relevant to Asia Pacific where malaria causes severe morbidity and mortality in all age groups, asymptomatic malaria infections are frequent, and the vaccine may not be effective against P. vivax.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Professors Peter Horby and Guy Thwaites recognised in Queen’s Birthday Honours

The pioneering work of members of the University of Oxford has been recognised in The Queen's Birthday Honours List. The honorands include Professor Peter Horby and six researchers that have played key roles in leading the University’s response to the Coronavirus pandemic, from the development of new vaccines to the discovery of new drug treatments. Professor Guy Thwaites is appointed a Member of the Order of the British Empire.

RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for patients hospitalised with COVID-19. Patients with COVID-19 are at increased risk of blood clots forming in their blood vessels, particularly in the lungs. Between November 2020 and March 2021, the RECOVERY trial included nearly 15,000 patients hospitalised with COVID-19 in an assessment of the effects of aspirin, which is widely used to reduce blood clotting in other diseases. There was no significant difference in the primary endpoint of 28-day mortality